Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 2 | 5 | 7 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Re: Clinical utility of multiple secondary combined tests in prostate cancer screening. Can J Urol. 2023 06; 30(3):11545.
-
Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report. Medicine (Baltimore). 2020 Feb; 99(8):e18889.
-
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 07 13; 377(2):132-142.
-
Predictors of prostate cancer screening using Andersen's Behavioral Model of Health Services Use. Urol Oncol. 2016 12; 34(12):529.e9-529.e14.
-
An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality. Br J Cancer. 2015 Jun 30; 113(1):166-72.
-
Magnetic resonance imaging-targeted vs. conventional transrectal ultrasound-guided prostate biopsy: single-institution, matched cohort comparison. Urol Oncol. 2015 Mar; 33(3):109.e1-6.
-
Prostate cancer: Could sensitive PSA assays expedite salvage radiotherapy? Nat Rev Urol. 2014 Jan; 11(1):14-5.
-
Piperine, a Bioactive Component of Pepper Spice Exerts Therapeutic Effects on Androgen Dependent and Androgen Independent Prostate Cancer Cells. PLoS One. 2013; 8(6):e65889.
-
Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics. 2013 Oct; 12(10):2935-51.
-
Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int. 2013 May; 111(6):934-40.